Guangliang Qiang1, Chaoyang Liang1, Rui Xu2, Jue Yan2, Yanyan Xu3, Ye Wang4, Jiping Da4, Bin Shi1, Yongqing Guo1, Deruo Liu1
1Department of Thoracic
Surgery, China-Japan Friendship Hospital, 2Department of Nuclear
Medicine, China-Japan Friendship Hospital, 3Department of Radiology,
China-Japan Friendship Hospital, 4Department of Pathology,
China-Japan Friendship Hospital
Objective:The aim of this study is to investigate
the correlation of histopathologic subtypes with epidermal growth factor
receptor (EGFR) mutations and 18F-fluorodeoxyglucose (FDG) uptake in
lung adenocarcinomas (ADCs). Method: A total of 97 patients with ADC who
underwent 18F-FDG positron emission tomography (PET)/CT scan prior
to surgical resection were retrospectively reviewed. All cases were divided
according to the new International Association for the Study of Lung
Cancer/American Thoracic Society/European Respiratory Society (IASLC/ATS/ERS)
classification, and graded by histopathologic scoring system. EGFR mutations
were identified as well. Clinicopathological factors associated with EGFR
mutation status were evaluated by univariate and multivariate analysis. Result:The frequency of EGFR mutation was 45.4% and associated with gender,
smoking, maximum standardized uptake value (SUVmax) and histopathologic score.
ADC patients with low SUVmax were more likely to carry EGFR mutations than
those with high SUVmax (P=0.018), and patients with lower
histopathologic score showed significantly lower SUVmax than those with higher
score (P<0.001). Moreover, histopathologic score and smoking history
were found to be independent predictors for EGFR mutation according to multivariate
logistic regression analysis. Conclusion: SUVmax and EGFR mutations
correlate to the stratification of lung ADCs based on the IASLC/ATS/ERS
classification. SUVmax promises a useful marker in stratifying preoperative
patients with lung ADCs and identifying EGFR mutations in case of unavailable
molecular diagnostics.
Key
Words: Adenocarcinoma Histologic subtype Epidermal growth
Copyright © 1998 - 2024 Chinese Society of Clinical Oncology(CSCO). All Rights Reserved
Contact Us
EMAIL:office@csco.org.cn
international@csco.org.cn
Phone:86(10)67726451 (Beijing)
86(25)84547290 (Nanjing)